| Titre : | The impact of maternal prenatal psychotropic use on children’s emotional and behavioral outcomes |
| Auteurs : | Seyedeh Neda Madani Mousavi ; Ecole des hautes études en santé publique (EHESP) (Rennes, FRA) |
| Type de document : | Mémoire |
| Année de publication : | 2024 |
| Description : | 49p. / fig., tabl. |
| Langues: | Anglais |
| Classement : | MPH/ (Mémoires MPH à partir de 2024) |
| Mots-clés : | Grossesse ; Santé maternelle & infantile ; Etat dépressif ; Trouble anxieux ; Médicament psychotrope ; Analyse ; Développement psychoaffectif ; Comportement ; Enfant ; France |
| Résumé : |
Introduction: Anxiety and depression are among the most prevalent complications of pregnancy. Research on the adverse effects of untreated anxiety and depression on child development, as well as the impact of pharmacotherapy for these conditions, have yielded inconsistent results. Among these studies, a limited number have focused on the child's emotional and behavioral outcomes. Thus, this study aimed to evaluate the association between in-utero exposure to psychotropic medication and adverse emotional and behavioral outcomes.
Method: This study included 1862 mother-child dyads from the EDEN cohort in France. Maternal prenatal psychotropic medication use was assessed through questionnaire data, combined with medical records and testing of meconium samples. Outcome data was gathered through the Strengths and Difficulties Questionnaire (SDQ) at four time points: 3, 5, 8, and 11 years old. Other than linear models, treating the SDQ results both cross-sectionally and longitudinally through SDQ trajectories, binomial, and multinomial logistic regression modes were implemented to investigate the association between the exposure and outcomes. These models controlled for several confounding factors. In addition, we tested whether the effects were modified by child sex. Results: All individuals who tested positive in the meconium test results, were also identified as having used psychotropic medications through the questionnaire. Among the exposed group, 55.56% initiated medication use during pregnancy, and among unexposed 13.08% used to consume psychotropics before pregnancy. All analyses evaluating the association of in-utero exposure to psychotropics with emotional and behavioral outcomes showed insignificant associations in both unadjusted and adjusted models. The interaction term for the child's sex was also insignificant in all models. Conclusion: The results of this study suggest that problematic emotional and behavioral outcomes in children are not among the adverse effects of using psychotropics during pregnancy; furthermore, this association does not appear to be modified by the child’s gender. |
| Diplôme : | Master MPH of public health |
| Plan de classement simplifié : | Master of Public Health - master international de Santé Publique (MPH) |
| En ligne : | https://documentation.ehesp.fr/memoires/2024/mph/seyedeh_neda_madani_mousavi.pdf |
Documents numériques (1)
 FullText URL |